AI-driven bioinformatics company Tempus partnered with Acuatate Therapeutics, a New York-based clinical-stage pharmaceutical company, to identify biomarker profiles for patients who benefit from Acutate’s GSK-3β inhibitor elraglusib.
Under the terms of the agreement, Tempus will provide its xF+ liquid biopsy panel, a clinical cell-free DNA test, and its DNA methylation test, as part of an ongoing clinical trial to identify patients who will respond to the drug. A phase I/II study will be conducted by Actuate Therapeutics to evaluate elraglusib alone and in combination with chemotherapy in patients that have refractory blood cancers and solid tumors. If successful, this will demonstrate a new way in which precision medicine can be incorporated into clinical development.
Actuate is a clinical-stage pharmaceutical company that is currently in the process of developing new treatments for cancer and inflammatory diseases. It has several ongoing studies of elraglusib, including pancreatic cancer, salivary gland carcinoma, myelofibrosis, and pediatric cancers.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.